Lawyer finder

Kevin Jones

Partner
Kevin Jones

A Wragge & Co trainee some years ago, I'm now in the firm's Corporate group. I focus on two sectors - life sciences, where I advise biotech and pharmaceuticals companies on M&A and fundraising - and creating investment structures for investments in real estate.

Tel: +44 (0)870 730 2823
Email: kevin_jones@wragge.com

Services: Corporate
Business sectors: Financial Services, Life Sciences

Best brains in...

Real estate funds and structuring - it needs both strong technical skills and commercial thinking to come up with the right approach and see it through to completion.

Highlight of your career so far?

I'd say selling nine hospitals for a large UK private medical company. Hospitals are phenomenally complicated businesses, which makes selling them far from easy. We had a private equity firm on the other side and the team did a great job in preparing, negotiating and executing a good deal for our client.

Most challenging job you've ever done?

When I was an associate I was part of a team advising TUI on its acquisition of Thomas Cook. I returned from a holiday to spend the next two weeks camped out in Allen & Overy's offices leading negotiations on this £1 billion acquisition, while the partner I was working with was working on the complex shareholders' agreement. I didn't get a lot of sleep during those two weeks!

What about outside the UK?

Most of my real estate work involves investment in real estate overseas, usually in Europe but, increasingly, clients are looking beyond to Russia and India, among other places. My team handles the English law advice and project manages firms in multiple jurisdictions, often leading the negotiations on the principal documents, even where they relate to overseas entities and structures.

How do you get under the skin of a client's business?

Spending time as part of its team. When I first became a partner I spent six months seconded to a healthcare client. I joined its legal team, working with them on a daily basis and finding out about the organisational dynamics. The experience made me and my team more effective advisers on subsequent transactions. I also learnt never to tell a client that I fully understand its business – unless you've worked in it, you don't!

Best example of a creative legal solution?

On one life sciences transaction, we agreed a deferred equity investment depending on certain conditions instead of a straightforward upfront fee. We had to work out how to determine a price, what would trigger the investment and various other factors. It was difficult but 12 months later, when we came to test the agreement, it stood up and the client has its investment.

What's your single greatest contribution to Wragge & Co's corporate responsibility?

I mentor students at the College of Law supervising their pro bono work. I am also helping the Association of Pharmaceutical Contract Manufacturers with its rules and general governance issues.

What's been written or said about you that you're most proud of?

At the end of my secondment, I got a leaving card from the team which everyone had signed and had lots of nice comments about my wisdom – not sure they weren't talking about someone else – and sense of humour. It was great getting those comments from people with whom I'd worked so closely.

Alerts

10.11.11

Earn-outs: everyone's a winner?

An earn-out is a means of ensuring that buyers do not overpay for (and sellers do not undersell) businesses that may be difficult to value upfront.

18.04.11

Planning ahead for new funding opportunities?

The Chancellor's March 2011 Budget introduces changes to the way companies can raise money from Venture Capital Trusts (VCTs) and through the Enterprise Investment Scheme (EIS). Due to take effect largely from April 2012, the changes are likely to open up significant new sources of funding.

18.04.11

AIM: New funding opportunities on the horizon for public companies

The Chancellor's March 2011 Budget introduces changes to the way companies can raise money from Venture Capital Trusts (VCTs) and through the Enterprise Investment Scheme (EIS).

 

Press releases

11.04.11

Wragge & Co advises on £91 million life sciences deal

Wragge & Co's corporate experts have advised Astex Therapeutics on its proposed £91 million cross-border acquisition by NASDAQ-listed SuperGen Inc.

28.02.11

Wragge & Co appointed to NSPCC's first legal panel

Wragge & Co has been appointed to the NSPCC's first legal panel. The four firms appointed will provide advice on areas including employment, intellectual property, commercial and IT.

27.07.10

Wragge & Co advises on cross-border life sciences M&A deal

Wragge & Co's Corporate group has advised new client Bioline group on its US $23.3 million (£15.2 million) cross-border acquisition by NASDAQ-listed Meridian Bioscience Inc.

01.06.10

Wragge & Co advises Eurotunnel on strategic rail freight acquisition

Wragge & Co's Corporate group has advised Europorte SAS, the rail freight subsidiary of cross-Channel operator Eurotunnel Groupe, on the acquisition of rail freight operator GBRf from FirstGroup plc for an undisclosed sum. The deal is the firm's first corporate instruction from Eurotunnel.

22.03.10

Wragge & Co secures FSA prospectus approval for £100 million fund

Wragge & Co LLP's Funds and Structuring team has advised Stirling Mortimer Limited in gaining Financial Services Authority (FSA) approval for the prospectus launching a fund worth up to £100 million

24.06.09

Wragge & Co advises Chroma Therapeutics on billion dollar deal double

Wragge & Co LLP's cross-firm life sciences practice has advised biotechnology company Chroma Therapeutics Limited on two simultaneous transactions completed in one day.

03.06.09

Wragge & Co funds experts advise on £100 million CISX-listed fund

Wragge & Co LLP has advised Stirling Mortimer Limited on launching a fund worth up to £100 million by securing Financial Services Authority (FSA) approval of the fund's prospectus.

17.06.08

Wragge & Co Life Sciences team advises Astex on $500 million drug discovery alliance

Wragge & Co LLP Life Sciences team has advised Astex Therapeutics Limited on a landmark $500 million drug discovery alliance with Janssen Pharmaceutica N.V.

 

Published articles

01.12.11

Earn-outs on trial

The recent High Court decision in Porton Capital Technology Funds and others v 3M UK Holdings Limited and another shows that agreeing to an earn-out as part of the purchase price for a business does not always produce the desired result.

 

Search for lawyer